Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo targets deadly thyroid cancer in small trial

NCT ID NCT06374602

Disease control Sponsor: Saint Petersburg State University, Russia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing whether two drugs, pembrolizumab and lenvatinib, can shrink tumors and improve survival in 20 people with anaplastic thyroid cancer, a rare and fast-growing cancer. Participants will receive both drugs and be monitored for response and side effects. The study aims to see if the combination can make inoperable tumors removable by surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pembrolizumab and lenvatinib
What this could lead to
If successful, this combination could offer a new treatment option for anaplastic thyroid cancer, potentially shrinking tumors and extending survival.
What could go wrong
This is a small, early-phase trial with only 20 participants. The drugs may cause significant side effects, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * immunohistochemically verified anaplastic thyroid cancer that is not eligible to R0-R1 surgery; * age ≥ 18 years; * functional status of ECOG 0-2; * adequate function of internal organs and bone marrow; * the ability to give written informed consent. Exclusion Criteria: * patients with a mutation in the BRAF V600 gene without previous targeted therapy with BRAF/MEK inhibitors; * patients with clinically significant hemoptysis and bleeding (for example, from the gastrointestinal tract or tumor-associated bleeding); * tumor invasion into large vessels; * patients with open wounds and fistulas; * contraindications to taking any of the studied drugs; * patients with poor functional status (ECOG 3-4); * continuous use of immunosuppressive therapy; * prior therapy with investigational drugs; * pregnancy, breast-feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anaplastic thyroid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

thyroid gland undifferentiated (anaplastic) carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anaplastic thyroid cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Saint Petersburg State University Hospital

    RECRUITING

    Saint Petersburg, 190020, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.